Panbela Therapeutics, Inc. has filed a prospectus supplement on July 30, 2024, to update and supplement information from its previous prospectus dated June 16, 2023. The supplement includes details of the issuance of 2,270,000 shares of common stock, various classes of warrants to purchase common stock, and up to 6,810,000 shares of common stock underlying the warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' and was last reported at $.35 per share on July 29, 2024. Additionally, Panbela Therapeutics and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., entered into a Loan Agreement with USWM, LLC on July 24, 2024, securing a term loan of $1,500,000. The loan is accompanied by a Term Promissory Note and is subject to certain conditions, including a maturity date of December...Show More

Panbela Therapeutics, Inc. has filed a prospectus supplement on July 30, 2024, to update and supplement information from its previous prospectus dated June 16, 2023. The supplement includes details of the issuance of 2,270,000 shares of common stock, various classes of warrants to purchase common stock, and up to 6,810,000 shares of common stock underlying the warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' and was last reported at $.35 per share on July 29, 2024. Additionally, Panbela Therapeutics and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., entered into a Loan Agreement with USWM, LLC on July 24, 2024, securing a term loan of $1,500,000. The loan is accompanied by a Term Promissory Note and is subject to certain conditions, including a maturity date of December 31, 2024, or upon the closing of a Qualifying Financing or Transaction. The proceeds from the loan are designated for specific uses, including payment to a contract research organization and other working capital purposes. The Loan Agreement includes customary covenants and events of default, and the company has pledged to complete a Qualifying Financing by the end of 2024 and a Qualifying Transaction by July 24, 2025. To secure the loan, Panbela Therapeutics and Cancer Prevention Pharmaceuticals have granted a first priority security interest in their rights in the Asset Purchase Agreement to the lender.